Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
Buy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS Treatment
Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), Keros Therapeutics (KROS)
Buy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial Health
Keros Therapeutics Seeks Fast Track FDA Nod for Novel Treatments Amidst Regulatory Uncertainty
Keros Therapeutics (KROS.US): The 2024 Q1 financial report achieved revenue of $83,000, with a previous value of $0; earnings per share of -$1.21, previous value of -$1.26, and expected value of -$1.34.
Keros Therapeutics (KROS.US): The 2024 Q1 financial report achieved revenue of $83,000, with a previous value of $0; earnings per share of -$1.21, previous value of -$1.26, and expected value of -$1.34.
Keros Therapeutics Q1 EPS $(1.21) Beats $(1.34) Estimate, Sales $83.00K
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which beat the analyst consensus estimate of $(1.34) by 9.7 percent. This is a 3.97 percent increase over losses of $(1.
Keros Therapeutics | 10-Q: Quarterly report
Keros Therapeutics Expects Cash and Cash Equivalents on Hand at March 31 Will Fund Expenses and Cap Expenditure Requirements Into 2027 >KROS
Keros Therapeutics Expects Cash and Cash Equivalents on Hand at March 31 Will Fund Expenses and Cap Expenditure Requirements Into 2027 >KROS
Keros Therapeutics 1Q Rev $83,000 >KROS
Keros Therapeutics 1Q Rev $83,000 >KROS
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000
08:01 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000
Keros Therapeutics 1Q Loss/Shr $1.21 >KROS
Keros Therapeutics 1Q Loss/Shr $1.21 >KROS
Keros Therapeutics Files Automatic Mixed Shelf
Is There An Opportunity With Keros Therapeutics, Inc.'s (NASDAQ:KROS) 41% Undervaluation?
Key Insights Keros Therapeutics' estimated fair value is US$94.52 based on 2 Stage Free Cash Flow to Equity Keros Therapeutics' US$55.78 share price signals that it might be 41% undervalued Our fa
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012
Keros Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Keros Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Piper Sandler Maintains Overweight on Keros Therapeutics, Maintains $105 Price Target
Piper Sandler analyst Joseph Catanzaro maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and maintains $105 price target.
No Data